Johnson & Johnson (JNJ.N)
JNJ.N on New York Stock Exchange
147.10USD
12 Dec 2018
147.10USD
12 Dec 2018
Change (% chg)
$0.60 (+0.41%)
$0.60 (+0.41%)
Prev Close
$146.50
$146.50
Open
$147.00
$147.00
Day's High
$148.49
$148.49
Day's Low
$147.00
$147.00
Volume
3,508,264
3,508,264
Avg. Vol
2,185,425
2,185,425
52-wk High
$148.97
$148.97
52-wk Low
$118.62
$118.62
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 1.95 | December | 13 Dec 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 5 | 5 | 5 | 6 |
| (2) OUTPERFORM | 4 | 4 | 4 | 4 |
| (3) HOLD | 8 | 8 | 9 | 9 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 1 | 1 | 1 | 1 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.33 | 2.33 | 2.37 | 2.30 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 13 | 20,210.30 | 20,604.00 | 19,967.00 | 20,945.70 |
| Quarter Ending Mar-19 | 7 | 20,153.50 | 20,554.30 | 19,730.00 | 20,070.00 |
| Year Ending Dec-18 | 17 | 81,347.80 | 81,791.00 | 80,601.00 | 80,671.60 |
| Year Ending Dec-19 | 18 | 82,826.70 | 85,219.00 | 80,628.00 | 84,057.80 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 16 | 1.95 | 1.97 | 1.92 | 1.91 |
| Quarter Ending Mar-19 | 9 | 2.19 | 2.31 | 2.06 | 2.08 |
| Year Ending Dec-18 | 19 | 8.16 | 8.18 | 8.14 | 7.86 |
| Year Ending Dec-19 | 20 | 8.62 | 8.82 | 8.38 | 8.37 |
| LT Growth Rate (%) | 5 | 8.12 | 9.00 | 6.00 | 7.03 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Sep-18 | 20,050.50 | 20,348.00 | 297.55 | 1.48 |
| Quarter Ending Jun-18 | 20,390.00 | 20,830.00 | 440.04 | 2.16 |
| Quarter Ending Mar-18 | 19,460.40 | 20,009.00 | 548.56 | 2.82 |
| Quarter Ending Dec-17 | 20,072.50 | 20,195.00 | 122.52 | 0.61 |
| Quarter Ending Sep-17 | 19,282.80 | 19,650.00 | 367.23 | 1.90 |
| Earnings (per share) | ||||
| Quarter Ending Sep-18 | 2.03 | 2.05 | 0.02 | 1.05 |
| Quarter Ending Jun-18 | 2.07 | 2.10 | 0.03 | 1.44 |
| Quarter Ending Mar-18 | 2.02 | 2.06 | 0.04 | 2.07 |
| Quarter Ending Dec-17 | 1.72 | 1.74 | 0.02 | 0.96 |
| Quarter Ending Sep-17 | 1.80 | 1.90 | 0.10 | 5.46 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 20,210.30 | 20,210.30 | 20,174.70 | 20,313.00 | 20,945.70 |
| Quarter Ending Mar-19 | 20,153.50 | 20,153.50 | 20,162.50 | 20,441.90 | 20,070.00 |
| Year Ending Dec-18 | 81,347.80 | 81,347.80 | 81,366.00 | 81,288.90 | 80,671.60 |
| Year Ending Dec-19 | 82,826.70 | 82,857.20 | 82,870.50 | 83,120.90 | 84,057.80 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 1.95 | 1.95 | 1.95 | 1.96 | 1.91 |
| Quarter Ending Mar-19 | 2.19 | 2.19 | 2.20 | 2.19 | 2.08 |
| Year Ending Dec-18 | 8.16 | 8.16 | 8.17 | 8.15 | 7.86 |
| Year Ending Dec-19 | 8.62 | 8.62 | 8.64 | 8.63 | 8.37 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Dec-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 1 | 0 | 1 |
| Earnings | ||||
| Quarter Ending Dec-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 1 | 0 | 1 |
Earnings vs. 
Estimates- J&J says its psoriasis drug superior to Novartis treatment in study
- UPDATE 2-J&J says its psoriasis drug superior to Novartis treatment in study
- J&J must face antitrust lawsuits over Remicade: judge
- J&J unit to pay $360 million to U.S. to resolve charity kickback probe
- UPDATE 3-J&J unit to pay $360 mln to U.S. to resolve charity kickback probe